Meiji Yasuda Asset Management Co Ltd. Trims Stock Position in Johnson & Johnson $JNJ

Meiji Yasuda Asset Management Co Ltd. cut its stake in Johnson & Johnson (NYSE:JNJ) by 2.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 110,240 shares of the company’s stock after selling 2,824 shares during the period. Johnson & Johnson comprises approximately 1.1% of Meiji Yasuda Asset Management Co Ltd.’s portfolio, making the stock its 11th largest position. Meiji Yasuda Asset Management Co Ltd.’s holdings in Johnson & Johnson were worth $22,814,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of JNJ. Abich Financial Wealth Management LLC purchased a new stake in Johnson & Johnson in the third quarter valued at $26,000. Cresta Advisors Ltd. purchased a new stake in Johnson & Johnson in the fourth quarter valued at $26,000. DecisionPoint Financial LLC lifted its position in Johnson & Johnson by 104.2% in the fourth quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock valued at $30,000 after acquiring an additional 75 shares during the last quarter. Family CFO Inc purchased a new stake in Johnson & Johnson in the fourth quarter valued at approximately $31,000. Finally, Bay Harbor Wealth Management LLC lifted its stake in Johnson & Johnson by 49.0% in the fourth quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company’s stock valued at $31,000 after buying an additional 49 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on JNJ shares. Weiss Ratings cut Johnson & Johnson from a “buy (b+)” rating to a “buy (b)” rating in a research note on Friday, April 24th. Daiwa Securities Group boosted their price objective on Johnson & Johnson from $237.00 to $246.00 and gave the company an “outperform” rating in a research note on Thursday, April 16th. Leerink Partners upgraded Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $265.00 price objective for the company in a research note on Wednesday, May 13th. Johnson Rice upgraded Johnson & Johnson from a “hold” rating to an “outperform” rating in a research note on Wednesday, May 13th. Finally, Guggenheim upped their target price on shares of Johnson & Johnson from $244.00 to $266.00 and gave the company a “buy” rating in a report on Monday, April 20th. Twenty research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $253.04.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson reported that nipocalimab was approved in China, adding another growth opportunity for its immunology portfolio and reinforcing the company’s global pipeline momentum. Reuters article on nipocalimab approval in China
• Positive Sentiment: The company unveiled the Shockwave C2 Aero Coronary IVL Catheter, a next-generation device for treating calcified coronary artery disease, highlighting continued innovation in its MedTech segment. Yahoo Finance article on next-gen catheter
• Positive Sentiment: Johnson & Johnson also announced a collaboration to build a global intelligent operating room network with Abu Dhabi’s Department of Health, which could strengthen its surgical technology and AI strategy over time. Yahoo Finance article on global intelligent OR network
• Neutral Sentiment: Recent commentary from analysts and market outlets continues to frame J&J as a relatively stable large-cap healthcare name with defensive characteristics, which may be helping investors rotate into the stock during market uncertainty. Yahoo Finance article on top stock reports

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $231.69 on Friday. Johnson & Johnson has a 12 month low of $149.04 and a 12 month high of $251.71. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.03 and a quick ratio of 0.77. The business has a 50 day simple moving average of $234.19 and a 200-day simple moving average of $223.20. The stock has a market capitalization of $557.73 billion, a PE ratio of 26.79, a price-to-earnings-growth ratio of 2.25 and a beta of 0.27.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, topping the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The business had revenue of $24.06 billion during the quarter, compared to analysts’ expectations of $23.60 billion. During the same quarter in the prior year, the business earned $2.77 earnings per share. The company’s quarterly revenue was up 9.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Equities analysts predict that Johnson & Johnson will post 11.57 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th will be paid a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a dividend yield of 2.3%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.30. The ex-dividend date is Tuesday, May 26th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 60.12%.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.